Photodynamic Therapy in the Treatment of Bladder Cancer: Past Challenges and Current Innovations
There are limited treatment options for patients with recurrent non-muscle-invasive bladder cancer. In this report, we will talk about the history of photodynamic therapy; although it showed encouraging therapeutic results, it was largely abandoned due to toxicity or bystander effects on normal cell...
Gespeichert in:
| Veröffentlicht in: | European urology focus 2018-07, Vol.4 (4), p.509-511 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 511 |
|---|---|
| container_issue | 4 |
| container_start_page | 509 |
| container_title | European urology focus |
| container_volume | 4 |
| creator | Railkar, Reema Agarwal, Piyush K. |
| description | There are limited treatment options for patients with recurrent non-muscle-invasive bladder cancer. In this report, we will talk about the history of photodynamic therapy; although it showed encouraging therapeutic results, it was largely abandoned due to toxicity or bystander effects on normal cells. Monoclonal antibody-conjugates represent an emerging therapeutic approach for malignancies that improves upon tumor specificity. The use of a monoclonal antibody-photosensitizer conjugate is a more selective method of delivering light therapy and has been termed “photoimmunotherapy”, which we will discuss in the last part of this report.
Photodynamic therapy (PDT) has been effective for bladder cancer; however, it has been complicated by toxicities due to nonspecific treatment of the urothelium. Photoimmunotherapy is a more targeted form of PDT that allows for selective tumor cell death with fewer toxicities. |
| doi_str_mv | 10.1016/j.euf.2018.08.005 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2094410775</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S2405456918302244</els_id><sourcerecordid>2094410775</sourcerecordid><originalsourceid>FETCH-LOGICAL-c353t-ef039c41ffbc373353e7620f4a1f62c8ed239ca97dc9ab1c3c0217256985a65b3</originalsourceid><addsrcrecordid>eNp9kMFqGzEQhkVpSUKaB8il6NiL3ZG02vW2p3ZJmkCgObhnVZZGtcyu5EragN8-Mk5LToWBGaRvfpiPkGsGSwas_bRb4uyWHNhqCbVAviEXvAG5aGTbv301n5OrnHcAwGTTiZU4I-cCWCMZ4xfk1-M2lmgPQU_e0PUWk94fqA-0bJGuE-oyYSg0Ovpt1NZiooMOBtNn-qhzocNWjyOG35ipDpYOc0pH_D6E-KSLjyG_J--cHjNevfRL8vP2Zj3cLR5-fL8fvj4sjJCiLNCB6E3DnNsY0Yn6hl3LwTWauZabFVpe_3XfWdPrDTPCAGcdr-etpG7lRlySj6fcfYp_ZsxFTT4bHEcdMM5ZceibhkHXyYqyE2pSzDmhU_vkJ50OioE6ulU7Vd2qo1sFteC48-Elft5MaP9t_DVZgS8nAOuRTx6TysZjVWV9QlOUjf4_8c_wy4ls</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2094410775</pqid></control><display><type>article</type><title>Photodynamic Therapy in the Treatment of Bladder Cancer: Past Challenges and Current Innovations</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Railkar, Reema ; Agarwal, Piyush K.</creator><creatorcontrib>Railkar, Reema ; Agarwal, Piyush K.</creatorcontrib><description>There are limited treatment options for patients with recurrent non-muscle-invasive bladder cancer. In this report, we will talk about the history of photodynamic therapy; although it showed encouraging therapeutic results, it was largely abandoned due to toxicity or bystander effects on normal cells. Monoclonal antibody-conjugates represent an emerging therapeutic approach for malignancies that improves upon tumor specificity. The use of a monoclonal antibody-photosensitizer conjugate is a more selective method of delivering light therapy and has been termed “photoimmunotherapy”, which we will discuss in the last part of this report.
Photodynamic therapy (PDT) has been effective for bladder cancer; however, it has been complicated by toxicities due to nonspecific treatment of the urothelium. Photoimmunotherapy is a more targeted form of PDT that allows for selective tumor cell death with fewer toxicities.</description><identifier>ISSN: 2405-4569</identifier><identifier>EISSN: 2405-4569</identifier><identifier>DOI: 10.1016/j.euf.2018.08.005</identifier><identifier>PMID: 30145112</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>5-Aminolevulinic acid ; Antibodies, Monoclonal - pharmacology ; BCG-refractory NMIBC ; Bladder cancer ; Hematoporphyrin ; Hexaminolevulinic acid ; Humans ; Immunoconjugates - pharmacology ; Neoplasm Invasiveness ; Neoplasm Recurrence, Local ; PDT ; Photochemotherapy - adverse effects ; Photochemotherapy - methods ; Photochemotherapy - trends ; Photodynamic therapy ; Photoimmunotherapy ; Photosensitizing Agents - pharmacology ; PIT ; Treatment Outcome ; Urinary Bladder Neoplasms - pathology ; Urinary Bladder Neoplasms - therapy ; Urothelial cancer</subject><ispartof>European urology focus, 2018-07, Vol.4 (4), p.509-511</ispartof><rights>2018</rights><rights>Copyright © 2018. Published by Elsevier B.V.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c353t-ef039c41ffbc373353e7620f4a1f62c8ed239ca97dc9ab1c3c0217256985a65b3</citedby><cites>FETCH-LOGICAL-c353t-ef039c41ffbc373353e7620f4a1f62c8ed239ca97dc9ab1c3c0217256985a65b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30145112$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Railkar, Reema</creatorcontrib><creatorcontrib>Agarwal, Piyush K.</creatorcontrib><title>Photodynamic Therapy in the Treatment of Bladder Cancer: Past Challenges and Current Innovations</title><title>European urology focus</title><addtitle>Eur Urol Focus</addtitle><description>There are limited treatment options for patients with recurrent non-muscle-invasive bladder cancer. In this report, we will talk about the history of photodynamic therapy; although it showed encouraging therapeutic results, it was largely abandoned due to toxicity or bystander effects on normal cells. Monoclonal antibody-conjugates represent an emerging therapeutic approach for malignancies that improves upon tumor specificity. The use of a monoclonal antibody-photosensitizer conjugate is a more selective method of delivering light therapy and has been termed “photoimmunotherapy”, which we will discuss in the last part of this report.
Photodynamic therapy (PDT) has been effective for bladder cancer; however, it has been complicated by toxicities due to nonspecific treatment of the urothelium. Photoimmunotherapy is a more targeted form of PDT that allows for selective tumor cell death with fewer toxicities.</description><subject>5-Aminolevulinic acid</subject><subject>Antibodies, Monoclonal - pharmacology</subject><subject>BCG-refractory NMIBC</subject><subject>Bladder cancer</subject><subject>Hematoporphyrin</subject><subject>Hexaminolevulinic acid</subject><subject>Humans</subject><subject>Immunoconjugates - pharmacology</subject><subject>Neoplasm Invasiveness</subject><subject>Neoplasm Recurrence, Local</subject><subject>PDT</subject><subject>Photochemotherapy - adverse effects</subject><subject>Photochemotherapy - methods</subject><subject>Photochemotherapy - trends</subject><subject>Photodynamic therapy</subject><subject>Photoimmunotherapy</subject><subject>Photosensitizing Agents - pharmacology</subject><subject>PIT</subject><subject>Treatment Outcome</subject><subject>Urinary Bladder Neoplasms - pathology</subject><subject>Urinary Bladder Neoplasms - therapy</subject><subject>Urothelial cancer</subject><issn>2405-4569</issn><issn>2405-4569</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kMFqGzEQhkVpSUKaB8il6NiL3ZG02vW2p3ZJmkCgObhnVZZGtcyu5EragN8-Mk5LToWBGaRvfpiPkGsGSwas_bRb4uyWHNhqCbVAviEXvAG5aGTbv301n5OrnHcAwGTTiZU4I-cCWCMZ4xfk1-M2lmgPQU_e0PUWk94fqA-0bJGuE-oyYSg0Ovpt1NZiooMOBtNn-qhzocNWjyOG35ipDpYOc0pH_D6E-KSLjyG_J--cHjNevfRL8vP2Zj3cLR5-fL8fvj4sjJCiLNCB6E3DnNsY0Yn6hl3LwTWauZabFVpe_3XfWdPrDTPCAGcdr-etpG7lRlySj6fcfYp_ZsxFTT4bHEcdMM5ZceibhkHXyYqyE2pSzDmhU_vkJ50OioE6ulU7Vd2qo1sFteC48-Elft5MaP9t_DVZgS8nAOuRTx6TysZjVWV9QlOUjf4_8c_wy4ls</recordid><startdate>201807</startdate><enddate>201807</enddate><creator>Railkar, Reema</creator><creator>Agarwal, Piyush K.</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201807</creationdate><title>Photodynamic Therapy in the Treatment of Bladder Cancer: Past Challenges and Current Innovations</title><author>Railkar, Reema ; Agarwal, Piyush K.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c353t-ef039c41ffbc373353e7620f4a1f62c8ed239ca97dc9ab1c3c0217256985a65b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>5-Aminolevulinic acid</topic><topic>Antibodies, Monoclonal - pharmacology</topic><topic>BCG-refractory NMIBC</topic><topic>Bladder cancer</topic><topic>Hematoporphyrin</topic><topic>Hexaminolevulinic acid</topic><topic>Humans</topic><topic>Immunoconjugates - pharmacology</topic><topic>Neoplasm Invasiveness</topic><topic>Neoplasm Recurrence, Local</topic><topic>PDT</topic><topic>Photochemotherapy - adverse effects</topic><topic>Photochemotherapy - methods</topic><topic>Photochemotherapy - trends</topic><topic>Photodynamic therapy</topic><topic>Photoimmunotherapy</topic><topic>Photosensitizing Agents - pharmacology</topic><topic>PIT</topic><topic>Treatment Outcome</topic><topic>Urinary Bladder Neoplasms - pathology</topic><topic>Urinary Bladder Neoplasms - therapy</topic><topic>Urothelial cancer</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Railkar, Reema</creatorcontrib><creatorcontrib>Agarwal, Piyush K.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European urology focus</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Railkar, Reema</au><au>Agarwal, Piyush K.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Photodynamic Therapy in the Treatment of Bladder Cancer: Past Challenges and Current Innovations</atitle><jtitle>European urology focus</jtitle><addtitle>Eur Urol Focus</addtitle><date>2018-07</date><risdate>2018</risdate><volume>4</volume><issue>4</issue><spage>509</spage><epage>511</epage><pages>509-511</pages><issn>2405-4569</issn><eissn>2405-4569</eissn><abstract>There are limited treatment options for patients with recurrent non-muscle-invasive bladder cancer. In this report, we will talk about the history of photodynamic therapy; although it showed encouraging therapeutic results, it was largely abandoned due to toxicity or bystander effects on normal cells. Monoclonal antibody-conjugates represent an emerging therapeutic approach for malignancies that improves upon tumor specificity. The use of a monoclonal antibody-photosensitizer conjugate is a more selective method of delivering light therapy and has been termed “photoimmunotherapy”, which we will discuss in the last part of this report.
Photodynamic therapy (PDT) has been effective for bladder cancer; however, it has been complicated by toxicities due to nonspecific treatment of the urothelium. Photoimmunotherapy is a more targeted form of PDT that allows for selective tumor cell death with fewer toxicities.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>30145112</pmid><doi>10.1016/j.euf.2018.08.005</doi><tpages>3</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2405-4569 |
| ispartof | European urology focus, 2018-07, Vol.4 (4), p.509-511 |
| issn | 2405-4569 2405-4569 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2094410775 |
| source | MEDLINE; Alma/SFX Local Collection |
| subjects | 5-Aminolevulinic acid Antibodies, Monoclonal - pharmacology BCG-refractory NMIBC Bladder cancer Hematoporphyrin Hexaminolevulinic acid Humans Immunoconjugates - pharmacology Neoplasm Invasiveness Neoplasm Recurrence, Local PDT Photochemotherapy - adverse effects Photochemotherapy - methods Photochemotherapy - trends Photodynamic therapy Photoimmunotherapy Photosensitizing Agents - pharmacology PIT Treatment Outcome Urinary Bladder Neoplasms - pathology Urinary Bladder Neoplasms - therapy Urothelial cancer |
| title | Photodynamic Therapy in the Treatment of Bladder Cancer: Past Challenges and Current Innovations |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T05%3A40%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Photodynamic%20Therapy%20in%20the%20Treatment%20of%20Bladder%20Cancer:%20Past%20Challenges%20and%20Current%20Innovations&rft.jtitle=European%20urology%20focus&rft.au=Railkar,%20Reema&rft.date=2018-07&rft.volume=4&rft.issue=4&rft.spage=509&rft.epage=511&rft.pages=509-511&rft.issn=2405-4569&rft.eissn=2405-4569&rft_id=info:doi/10.1016/j.euf.2018.08.005&rft_dat=%3Cproquest_cross%3E2094410775%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2094410775&rft_id=info:pmid/30145112&rft_els_id=S2405456918302244&rfr_iscdi=true |